How to treat methytlith-positive late-stage solid tumor? The effectiveness of the new T-cell therapy TC-210 is significant.

TCR2, a !---- immunotherapy company that is developing a range of new T-cell therapies for cancer patients, is currently in phase I/II clinical phase to treat methlopathy-positive non-small cell lung cancer (NSCLC), ovarian cancer, pleural/peritoneal lylthyosome and bile duct cancer.TCR2 announced today that in Phase I/II clinical trials, all five patients showed tumor abating after treatment with TC-210, and only one patient showed non-hematological toxicity associated with TC-210, free of neurotoxicity. Dr. Garry Menzel, President and CEO ofTCR2, said, "We are pleased to see the clinical benefits of TC-210 in patients with advanced solid tumors.patients with solid tumors have few treatment options, and methlitoidoid-positive patients represent unmet medical needs."mesothelin is a cell surface glycoprotein with a molecular weight of 40kDa, highly expressed in a variety of tumor tissues, but also in the normal pleural, heart bags and peritoneal interleal cells.mesothelin is also an early biomarker of pancreatic cancer..